MedTrace Logo

SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

NCT04269642 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2021-04-12

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of sustained release (SR)-Exenatide (PT320, Q1W and Q2W) in the treatment of patients with early Parkinson's disease (PD).

Conditions

  • Early Parkinson's Disease

Interventions

DRUG

PT320 2.0mg Placebo

PT320 2.0mg Placebo

DRUG

PT320 2.0 mg

Exenatide slowly released formulation

DRUG

PT320 2.5 mg

Exenatide slowly released formulation

Sponsors & Collaborators

  • Peptron, Inc.

    lead INDUSTRY

Principal Investigators

  • Min Ho Ihm · Peptron, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-19
Primary Completion
2021-09-29
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04269642 on ClinicalTrials.gov